Table 2.
|
|
DURATION-1 |
DURATION-5 |
DURATION-2 |
DURATION-3 |
|||||
---|---|---|---|---|---|---|---|---|---|---|
ExQW range | ExQW | ExBID | ExQW | ExBID | ExQW | Sitagliptin | Pioglitazone | ExQW | Glargine | |
Glycemic control | ||||||||||
HbA1c (%) to goal | ||||||||||
<7% | 58–71 | 71a | 51ab | 58 | 30b | 59 | 31b | 44b | 60 | 48b |
≤6.5% | 39–45 | 45a | 38a | 41 | 16b | 39 | 16b | 27b | 43a | 28ab |
End point mean HbA1c (%) | 6.4–7.2 | 6.4 | 6.8 | 7.1 | 7.7 | 7.2 | 7.7 | 7.4 | 6.8 | 7.0 |
Markers of CV risk | ||||||||||
Δ SBP (mm Hg) | −2.9 to −4.7 | −4.7c | −3.4c | −2.9c | −1.2 | −3.6c | +0.2b | −1.6 | −3.0c | −1.0 |
ΔTotal cholesterol (mg/dL) | −0.6 to−15 | −11.9c | −3.8b | −15c | +0.6b | −0.6 | +3.1 | +6.2c | −4.6c | −1.5 |
Δ LDL cholesterol (mg/dL) | −1 to −6 | −4.9c | +1.2b | −6.4c | +2.8b | −1.0 | +1.8 | +1.8 | −1.9 | +1.5 |
Δ HDL cholesterol (mg/dL) | −1 to +2 | −0.9 | −1.3c | 0 | +1.3 | +2.0c | +2.0c | +6.2bc | 0 | +0.4 |
Δ Triglycerides (%) | −4 to −15 | −15c | −11c | −6 | −1 | −5 | −5 | −16bc | −4 | −11c |
Data on file at Amylin Pharmaceuticals.
Treatment difference versus ExQW, P<0.05.
Significant difference versus baseline, P<0.05.
CV, cardiovascular; ExBID, exenatide twice daily; ExQW, exenatide once weekly; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.